Literature DB >> 17210770

Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program.

Ronald N Jones1, Matthew G Stilwell, Patricia A Hogan, Daniel J Sheehan.   

Abstract

Linezolid was tested against 32 species of uncommonly isolated gram-positive organisms (3,251 strains) by reference MIC methods and found to be highly active (MIC50 range, 0.25 to 2 microg/ml; MIC90 range, 0.25 to 2 microg/ml). Only one isolate (viridans group streptococcus; 0.03% of tested strains) was resistant to linezolid.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17210770      PMCID： PMC1855453          DOI： 10.1128/AAC.01496-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.

Authors:  R N Jones; C H Ballow; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2001 May-Jun       Impact factor: 2.803

2.  Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.

Authors:  R N Jones; T R Anderegg; D J Biedenbach
Journal:  Clin Microbiol Infect       Date:  2003-06       Impact factor: 8.067

Review 3.  Antimicrobial resistance to linezolid.

Authors:  Venkata G Meka; Howard S Gold
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

4.  Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001).

Authors:  Ronald N Jones
Journal:  Semin Respir Crit Care Med       Date:  2003-02       Impact factor: 3.119

5.  Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Authors:  Ronald N Jones; James E Ross; Thomas R Fritsche; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2005-12-02       Impact factor: 5.790

6.  Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

Authors:  Tamara R Anderegg; Helio S Sader; Thomas R Fritsche; James E Ross; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2005-07       Impact factor: 5.283

7.  In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.

Authors:  Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 8.  Oxazolidinone antibiotics.

Authors:  D J Diekema; R N Jones
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

9.  Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS).

Authors:  Charles H Ballow; Douglas J Biedenbach; Flavia Rossi; Ronald N Jones
Journal:  Braz J Infect Dis       Date:  2002-06       Impact factor: 1.949

10.  Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.

Authors:  Alan H Mutnick; Douglas J Biedenbach; John D Turnidge; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2002-05       Impact factor: 2.803
View more
  3 in total

1.  Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.

Authors:  Andrea Marra; Lucinda Lamb; Ivette Medina; David George; Glenn Gibson; Joel Hardink; Jady Rugg; Jeffrey Van Deusen; John P O'Donnell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-18       Impact factor: 5.191

2.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

3.  Occurrence of Corynebacterium striatum as an emerging antibiotic-resistant nosocomial pathogen in a Tunisian hospital.

Authors:  Sana Alibi; Asma Ferjani; Jalel Boukadida; María Eliecer Cano; Marta Fernández-Martínez; Luis Martínez-Martínez; Jesús Navas
Journal:  Sci Rep       Date:  2017-08-28       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.